NR4A1 and cancer: A large proportion of patients enroled had stage II disease (62.6% in cohort A, 61.5% in cohort B, and 73.2% in cohort C, P = 0.57), hormone receptor (HR)-positive cancer (67.7% in cohort A, 76.9% in cohort B, and 61.0% in cohort C, P = 0.40), and Ki67 levels ≥20% (82.3% in cohort A, 73.1% in cohort B, and 78.0% in cohort C, P = 0.62).